Last reviewed · How we verify
Clostridium butyricum capsules
Clostridium butyricum is a live biotherapeutic agent that produces butyrate in the colon to promote beneficial microbiota composition and intestinal barrier function.
Clostridium butyricum is a live biotherapeutic agent that produces butyrate in the colon to promote beneficial microbiota composition and intestinal barrier function. Used for Diarrhea associated with dysbiosis, Irritable bowel syndrome, Inflammatory bowel conditions.
At a glance
| Generic name | Clostridium butyricum capsules |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | Live biotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Clostridium butyricum is a spore-forming bacterium that colonizes the gut and ferments dietary fiber to produce short-chain fatty acids, particularly butyrate. Butyrate serves as a primary energy source for colonocytes, strengthens the intestinal epithelial barrier, and modulates immune responses through histone deacetylase inhibition and G-protein coupled receptor signaling. This mechanism helps restore dysbiotic microbiota and improve gastrointestinal health.
Approved indications
- Diarrhea associated with dysbiosis
- Irritable bowel syndrome
- Inflammatory bowel conditions
Common side effects
- Gastrointestinal disturbance
- Abdominal discomfort
- Flatulence
Key clinical trials
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma (PHASE4)
- The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer (PHASE4)
- A Probiotic Based Intervention in Pregnancies Complicated by GDM (PHASE2)
- Role of Akkermansia Muciniphila in Acne Vulgaris (EARLY_PHASE1)
- OsteoPreP: Food Supplements for Postmenopausal Bone Health (PHASE4)
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (PHASE1)
- Next-Generation Synbiotic in Individuals With Overweight or Obesity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: